Article
Tau antibody chimerization alters its charge and binding, thereby reducing its cellular uptake and efficacy
22 Mar 2019
Abstract excerpt
BACKGROUND: Bringing antibodies from pre-clinical studies to human trials requires humanization, but this process may alter properties that are crucial for efficacy. Since pathological tau protein is primarily intraneuronal in Alzheimer's disease, the most efficacious antibodies should work both intra- and extracellularly. Thus, changes which impact uptake or antibody binding will affect antibody efficacy....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.